Associated Papers
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW et al.
Molecular Oncology, 2023
36892268 (PubMed )
Supplement: MOL2-17-2000-s008.pdf
Select a paper to view details